Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDER’s Neurology Division Prepares For New Leadership With Director Katz’s Retirement

This article was originally published in The Pink Sheet Daily

Executive Summary

Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.

You may also be interested in...



CNS Candidates Mostly Offer New Approaches In Established Categories

CNS candidates range from new mechanisms in multiple sclerosis to the first orexin antagonist for insomnia and refinements in neurotransmitter targeting for schizophrenia and depression. A second amyloid imaging agent could reach the market to aid in diagnosis of Alzheimer’s disease.

FDA Draft Guidance On Drug Development For Early Alzheimer's A Call For Action On Biomarkers

FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease offers options for trial design, but without biomarkers to accurately diagnose the disease and track its progression, a trial could be doomed from the start.

Class Labeling For Anti-epileptics Embraces Lessons From Antidepressants

Anti-epileptic drug sponsors have until mid-January to decide whether to fight FDA-mandated labeling changes and a REMS program after a meta-analysis showed a statistically significant increase in suicidality.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel